25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Actinium Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Actinium Pharmaceuticals Inc together

I guess you are interested in Actinium Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Actinium Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Actinium Pharmaceuticals Inc

I send you an email if I find something interesting about Actinium Pharmaceuticals Inc.

Quick analysis of Actinium Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Actinium Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$1.47
Expected worth in 1 year
$1.02
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.45
Return On Investment
-6.3%

For what price can you sell your share?

Current Price per Share
$7.11
Expected price per share
$6.26 - $10.46
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Actinium Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$7.11

Intrinsic Value Per Share

$-7.94 - $-8.67

Total Value Per Share

$-6.46 - $-7.20

2. Growth of Actinium Pharmaceuticals Inc (5 min.)




Is Actinium Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$43.8m$68.2m-$24m-54.4%

How much money is Actinium Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$11.6m-$9.3m-$2.2m-19.6%
Net Profit Margin-2,877.8%-11,545.3%--

How much money comes from the company's main activities?

3. Financial Health of Actinium Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#474 / 982

Most Revenue
#752 / 982

Most Profit
#599 / 982

Most Efficient
#827 / 982
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Actinium Pharmaceuticals Inc? (5 min.)

Welcome investor! Actinium Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Actinium Pharmaceuticals Inc.

What can you expect buying and holding a share of Actinium Pharmaceuticals Inc?

First you should know what it really means to hold a share of Actinium Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Actinium Pharmaceuticals Inc is $7.11. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Actinium Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Actinium Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.47. Based on the TTM, the Book Value Change Per Share is $-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Actinium Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.29-4.1%-0.39-5.5%-0.33-4.6%-0.26-3.6%-0.20-2.9%
Usd Book Value Change Per Share0.253.5%-0.11-1.6%-0.10-1.4%0.060.9%0.050.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.253.5%-0.11-1.6%-0.10-1.4%0.060.9%0.050.7%
Usd Price Per Share7.83-6.56-8.07-5.64-3.88-
Price to Earnings Ratio-6.72--4.44--6.06--5.58--3.33-
Price-to-Total Gains Ratio31.19--15.47--28.30-154.66-65.37-
Price to Book Ratio5.32-4.42-3.65-3.00-3.61-
Price-to-Total Gains Ratio31.19--15.47--28.30-154.66-65.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.11
Number of shares140
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.110.06
Usd Total Gains Per Share-0.110.06
Gains per Quarter (140 shares)-15.699.05
Gains per Year (140 shares)-62.7636.21
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-63-7303626
20-126-13607262
30-188-199010998
40-251-2620145134
50-314-3250181170
60-377-3880217206
70-439-4510253242
80-502-5140290278
90-565-5770326314
100-628-6400362350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%4.066.00.05.7%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%7.012.01.035.0%13.026.01.032.5%17.050.03.024.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%4.00.016.020.0%4.00.036.010.0%4.00.066.05.7%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%14.026.00.035.0%18.050.02.025.7%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Actinium Pharmaceuticals Inc

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for people with relapsed and refractory acute myeloid leukemia for bone marrow transplant; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.

Fundamental data was last updated by Penke on 2024-07-17 10:08:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Actinium Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Actinium Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Actinium Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,877.8%+2,877.8%
TTM-2,877.8%YOY-11,545.3%+8,667.5%
TTM-2,877.8%5Y-4,928.0%+2,050.2%
5Y-4,928.0%10Y-2,464.0%-2,464.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--169.1%+169.1%
TTM-2,877.8%-209.9%-2,667.9%
YOY-11,545.3%-234.9%-11,310.4%
5Y-4,928.0%-392.9%-4,535.1%
10Y-2,464.0%-512.4%-1,951.6%
1.1.2. Return on Assets

Shows how efficient Actinium Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Actinium Pharmaceuticals Inc to the Biotechnology industry mean.
  • -9.8% Return on Assets means that Actinium Pharmaceuticals Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Actinium Pharmaceuticals Inc:

  • The MRQ is -9.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.8%TTM-12.9%+3.1%
TTM-12.9%YOY-8.3%-4.6%
TTM-12.9%5Y-14.7%+1.8%
5Y-14.7%10Y-23.0%+8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.8%-11.8%+2.0%
TTM-12.9%-11.9%-1.0%
YOY-8.3%-11.2%+2.9%
5Y-14.7%-13.3%-1.4%
10Y-23.0%-14.7%-8.3%
1.1.3. Return on Equity

Shows how efficient Actinium Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Actinium Pharmaceuticals Inc to the Biotechnology industry mean.
  • -19.8% Return on Equity means Actinium Pharmaceuticals Inc generated $-0.20 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Actinium Pharmaceuticals Inc:

  • The MRQ is -19.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -26.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.8%TTM-26.1%+6.3%
TTM-26.1%YOY-14.0%-12.1%
TTM-26.1%5Y-24.7%-1.4%
5Y-24.7%10Y-35.2%+10.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.8%-14.1%-5.7%
TTM-26.1%-15.2%-10.9%
YOY-14.0%-14.0%0.0%
5Y-24.7%-18.8%-5.9%
10Y-35.2%-19.4%-15.8%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Actinium Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Actinium Pharmaceuticals Inc is operating .

  • Measures how much profit Actinium Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Actinium Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3,192.3%+3,192.3%
TTM-3,192.3%YOY-12,281.1%+9,088.8%
TTM-3,192.3%5Y-5,149.1%+1,956.8%
5Y-5,149.1%10Y-2,574.6%-2,574.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--346.7%+346.7%
TTM-3,192.3%-218.9%-2,973.4%
YOY-12,281.1%-238.4%-12,042.7%
5Y-5,149.1%-400.7%-4,748.4%
10Y-2,574.6%-514.0%-2,060.6%
1.2.2. Operating Ratio

Measures how efficient Actinium Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM32.173-32.173
TTM32.173YOY125.892-93.719
TTM32.1735Y52.407-20.234
5Y52.40710Y26.204+26.204
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.003-3.003
TTM32.1733.247+28.926
YOY125.8923.454+122.438
5Y52.4075.124+47.283
10Y26.2046.570+19.634
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Actinium Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Actinium Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.59 means the company has $10.59 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 10.587. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.028. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.587TTM10.028+0.559
TTM10.028YOY13.846-3.818
TTM10.0285Y11.262-1.234
5Y11.26210Y7.971+3.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.5873.793+6.794
TTM10.0284.066+5.962
YOY13.8464.958+8.888
5Y11.2625.996+5.266
10Y7.9716.335+1.636
1.3.2. Quick Ratio

Measures if Actinium Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Actinium Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 10.42 means the company can pay off $10.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 10.424. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.748. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.424TTM9.748+0.675
TTM9.748YOY13.544-3.796
TTM9.7485Y11.008-1.259
5Y11.00810Y7.758+3.250
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.4243.192+7.232
TTM9.7483.581+6.167
YOY13.5444.835+8.709
5Y11.0085.948+5.060
10Y7.7586.457+1.301
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Actinium Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Actinium Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Actinium Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.50 means that Actinium Pharmaceuticals Inc assets are financed with 50.4% credit (debt) and the remaining percentage (100% - 50.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 0.504. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.508. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.504TTM0.508-0.004
TTM0.508YOY0.401+0.106
TTM0.5085Y0.296+0.211
5Y0.29610Y0.316-0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5040.328+0.176
TTM0.5080.339+0.169
YOY0.4010.286+0.115
5Y0.2960.367-0.071
10Y0.3160.383-0.067
1.4.2. Debt to Equity Ratio

Measures if Actinium Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Actinium Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 101.5% means that company has $1.01 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 1.015. The company is able to pay all its debts with equity. +1
  • The TTM is 1.040. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.015TTM1.040-0.026
TTM1.040YOY0.675+0.365
TTM1.0405Y0.533+0.507
5Y0.53310Y0.583-0.049
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0150.363+0.652
TTM1.0400.412+0.628
YOY0.6750.367+0.308
5Y0.5330.438+0.095
10Y0.5830.476+0.107
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Actinium Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Actinium Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Actinium Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -6.72 means the investor is paying $-6.72 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Actinium Pharmaceuticals Inc:

  • The EOD is -6.106. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.724. Based on the earnings, the company is expensive. -2
  • The TTM is -4.435. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.106MRQ-6.724+0.618
MRQ-6.724TTM-4.435-2.289
TTM-4.435YOY-6.059+1.623
TTM-4.4355Y-5.578+1.143
5Y-5.57810Y-3.330-2.249
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.106-2.652-3.454
MRQ-6.724-3.015-3.709
TTM-4.435-2.881-1.554
YOY-6.059-3.574-2.485
5Y-5.578-6.225+0.647
10Y-3.330-6.348+3.018
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Actinium Pharmaceuticals Inc:

  • The EOD is -7.169. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.895. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.233. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.169MRQ-7.895+0.726
MRQ-7.895TTM-5.233-2.662
TTM-5.233YOY-5.754+0.521
TTM-5.2335Y-5.948+0.715
5Y-5.94810Y-4.848-1.100
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.169-3.251-3.918
MRQ-7.895-3.787-4.108
TTM-5.233-3.794-1.439
YOY-5.754-5.044-0.710
5Y-5.948-8.020+2.072
10Y-4.848-8.669+3.821
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Actinium Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.32 means the investor is paying $5.32 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Actinium Pharmaceuticals Inc:

  • The EOD is 4.828. Based on the equity, the company is fair priced.
  • The MRQ is 5.317. Based on the equity, the company is overpriced. -1
  • The TTM is 4.421. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.828MRQ5.317-0.489
MRQ5.317TTM4.421+0.896
TTM4.421YOY3.652+0.769
TTM4.4215Y3.002+1.420
5Y3.00210Y3.615-0.613
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.8281.991+2.837
MRQ5.3172.271+3.046
TTM4.4212.296+2.125
YOY3.6522.385+1.267
5Y3.0023.670-0.668
10Y3.6154.162-0.547
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Actinium Pharmaceuticals Inc.

3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Actinium Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.251-0.112+145%-0.098+139%0.065+288%0.048+422%
Book Value Per Share--1.4731.485-1%2.293-36%1.710-14%1.089+35%
Current Ratio--10.58710.028+6%13.846-24%11.262-6%7.971+33%
Debt To Asset Ratio--0.5040.508-1%0.401+25%0.296+70%0.316+60%
Debt To Equity Ratio--1.0151.040-2%0.675+50%0.533+90%0.583+74%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Eps---0.291-0.390+34%-0.327+12%-0.258-11%-0.205-30%
Free Cash Flow Per Share---0.248-0.333+34%-0.009-96%-0.176-29%-0.171-31%
Free Cash Flow To Equity Per Share--0.248-0.091+137%0.191+29%0.121+104%0.064+285%
Gross Profit Margin--1.0251.006+2%1.000+2%1.001+2%1.001+2%
Intrinsic Value_10Y_max---8.669--------
Intrinsic Value_10Y_min---7.935--------
Intrinsic Value_1Y_max---0.712--------
Intrinsic Value_1Y_min---0.715--------
Intrinsic Value_3Y_max---2.259--------
Intrinsic Value_3Y_min---2.231--------
Intrinsic Value_5Y_max---3.950--------
Intrinsic Value_5Y_min---3.825--------
Market Cap211760685.000-10%233204805.000195454218.750+19%240427303.750-3%167947965.160+39%115616940.944+102%
Net Profit Margin----28.7780%-115.4530%-49.2800%-24.6400%
Operating Margin----31.9230%-122.8110%-51.4910%-25.7460%
Operating Ratio---32.173-100%125.892-100%52.407-100%26.204-100%
Pb Ratio4.828-10%5.3174.421+20%3.652+46%3.002+77%3.615+47%
Pe Ratio-6.106+9%-6.724-4.435-34%-6.059-10%-5.578-17%-3.330-50%
Price Per Share7.110-10%7.8306.563+19%8.073-3%5.639+39%3.882+102%
Price To Free Cash Flow Ratio-7.169+9%-7.895-5.233-34%-5.754-27%-5.948-25%-4.848-39%
Price To Total Gains Ratio28.318-10%31.185-15.471+150%-28.300+191%154.662-80%65.370-52%
Quick Ratio--10.4249.748+7%13.544-23%11.008-5%7.758+34%
Return On Assets---0.098-0.129+31%-0.083-15%-0.147+49%-0.230+134%
Return On Equity---0.198-0.261+32%-0.140-29%-0.247+25%-0.352+78%
Total Gains Per Share--0.251-0.112+145%-0.098+139%0.065+288%0.048+422%
Usd Book Value--43857000.00044224000.000-1%68281250.000-36%50918410.100-14%32438370.275+35%
Usd Book Value Change Per Share--0.251-0.112+145%-0.098+139%0.065+288%0.048+422%
Usd Book Value Per Share--1.4731.485-1%2.293-36%1.710-14%1.089+35%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Eps---0.291-0.390+34%-0.327+12%-0.258-11%-0.205-30%
Usd Free Cash Flow---7385000.000-9930000.000+34%-271750.000-96%-5230471.600-29%-5096099.175-31%
Usd Free Cash Flow Per Share---0.248-0.333+34%-0.009-96%-0.176-29%-0.171-31%
Usd Free Cash Flow To Equity Per Share--0.248-0.091+137%0.191+29%0.121+104%0.064+285%
Usd Market Cap211760685.000-10%233204805.000195454218.750+19%240427303.750-3%167947965.160+39%115616940.944+102%
Usd Price Per Share7.110-10%7.8306.563+19%8.073-3%5.639+39%3.882+102%
Usd Profit---8670000.000-11612750.000+34%-9331500.000+8%-7551055.700-13%-6506816.525-25%
Usd Revenue---20250.000-100%51000.000-100%118450.000-100%59225.000-100%
Usd Total Gains Per Share--0.251-0.112+145%-0.098+139%0.065+288%0.048+422%
 EOD+2 -6MRQTTM+26 -6YOY+15 -175Y+15 -1910Y+20 -14

4.2. Fundamental Score

Let's check the fundamental score of Actinium Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.106
Price to Book Ratio (EOD)Between0-14.828
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.424
Current Ratio (MRQ)Greater than110.587
Debt to Asset Ratio (MRQ)Less than10.504
Debt to Equity Ratio (MRQ)Less than11.015
Return on Equity (MRQ)Greater than0.15-0.198
Return on Assets (MRQ)Greater than0.05-0.098
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Actinium Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose7.240
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets88,352
Total Liabilities44,495
Total Stockholder Equity43,857
 As reported
Total Liabilities 44,495
Total Stockholder Equity+ 43,857
Total Assets = 88,352

Assets

Total Assets88,352
Total Current Assets85,373
Long-term Assets2,979
Total Current Assets
Cash And Cash Equivalents 84,057
Other Current Assets 1,316
Total Current Assets  (as reported)85,373
Total Current Assets  (calculated)85,373
+/-0
Long-term Assets
Property Plant Equipment 2,663
Other Assets 0
Long-term Assets  (as reported)2,979
Long-term Assets  (calculated)2,663
+/- 316

Liabilities & Shareholders' Equity

Total Current Liabilities8,064
Long-term Liabilities36,431
Total Stockholder Equity43,857
Total Current Liabilities
Short-term Debt 551
Accounts payable 7,513
Other Current Liabilities -35,000
Total Current Liabilities  (as reported)8,064
Total Current Liabilities  (calculated)-26,936
+/- 35,000
Long-term Liabilities
Capital Lease Obligations 1,982
Long-term Liabilities  (as reported)36,431
Long-term Liabilities  (calculated)1,982
+/- 34,449
Total Stockholder Equity
Common Stock29
Retained Earnings -346,253
Other Stockholders Equity 390,081
Total Stockholder Equity (as reported)43,857
Total Stockholder Equity (calculated)43,857
+/-0
Other
Capital Stock29
Cash and Short Term Investments 84,057
Common Stock Shares Outstanding 27,886
Current Deferred Revenue35,000
Liabilities and Stockholders Equity 88,352
Net Debt -82,075
Net Invested Capital 43,857
Net Working Capital 77,309
Property Plant and Equipment Gross 3,423
Short Long Term Debt Total 1,982



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-30
> Total Assets 
0
0
0
0
6
6
2
2
2
2
2
2
2
2
1
35
0
0
0
0
0
0
0
0
0
5,789
3,357
5,735
4,050
5,766
6,560
15,447
12,598
7,569
20,055
26,330
25,050
26,588
23,344
21,573
17,262
22,529
18,245
12,977
21,721
18,337
28,141
22,585
15,702
14,889
12,235
21,819
16,318
11,670
11,670
55,958
50,527
66,397
75,097
84,454
84,479
80,388
74,562
121,800
116,816
114,192
102,026
99,051
88,944
81,445
88,352
88,35281,44588,94499,051102,026114,192116,816121,80074,56280,38884,47984,45475,09766,39750,52755,95811,67011,67016,31821,81912,23514,88915,70222,58528,14118,33721,72112,97718,24522,52917,26221,57323,34426,58825,05026,33020,0557,56912,59815,4476,5605,7664,0505,7353,3575,78900000000035122222222660000
   > Total Current Assets 
0
0
0
0
6
6
2
2
2
2
2
2
2
2
1
35
0
0
0
0
0
0
0
0
0
5,786
3,357
5,735
4,043
5,752
6,546
15,279
12,423
7,407
19,919
26,210
24,920
26,481
23,179
21,413
17,121
22,390
18,119
12,466
21,215
17,839
27,647
22,084
15,157
14,330
10,265
19,945
14,551
10,088
10,088
54,508
49,180
64,925
73,747
83,171
83,261
79,749
74,053
118,297
113,423
110,942
98,546
95,537
85,596
78,263
85,373
85,37378,26385,59695,53798,546110,942113,423118,29774,05379,74983,26183,17173,74764,92549,18054,50810,08810,08814,55119,94510,26514,33015,15722,08427,64717,83921,21512,46618,11922,39017,12121,41323,17926,48124,92026,21019,9197,40712,42315,2796,5465,7524,0435,7353,3575,78600000000035122222222660000
       Cash And Cash Equivalents 
0
0
0
0
6
6
2
2
2
2
2
2
2
2
1
0
0
0
0
0
0
0
0
0
0
5,619
3,240
5,650
3,990
5,533
5,878
14,671
11,751
6,707
19,285
25,952
24,762
25,643
22,207
20,455
15,527
20,519
17,088
11,456
20,542
17,400
26,764
21,474
14,805
13,673
9,925
19,521
14,313
9,254
9,254
53,466
48,234
63,560
72,253
81,912
82,032
77,829
72,019
116,330
111,815
108,910
94,522
91,276
82,978
76,677
84,057
84,05776,67782,97891,27694,522108,910111,815116,33072,01977,82982,03281,91272,25363,56048,23453,4669,2549,25414,31319,5219,92513,67314,80521,47426,76417,40020,54211,45617,08820,51915,52720,45522,20725,64324,76225,95219,2856,70711,75114,6715,8785,5333,9905,6503,2405,6190000000000122222222660000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
11
19
11
35
35
35
35
35
0
0
0
0
40
40
40
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000004040400000353535353511191111000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
56
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000560000000000000000000000000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35
0
0
0
0
0
0
0
0
0
167
117
84
53
218
668
608
672
689
623
238
146
838
972
957
1,593
1,871
1,031
1,010
673
439
884
610
351
656
340
424
238
48
834
1,042
946
1,365
1,494
1,259
1,229
1,920
2,034
1,967
1,608
2,032
4,024
4,261
2,618
1,586
1,316
1,3161,5862,6184,2614,0242,0321,6081,9672,0341,9201,2291,2591,4941,3659461,042834482384243406563516108844396731,0101,0311,8711,593957972838146238623689672608668218538411716700000000035000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
0
7
14
14
168
176
162
136
121
130
106
165
160
141
138
126
511
506
498
493
500
546
560
1,970
1,874
1,767
1,583
1,583
1,450
1,347
1,472
1,350
1,283
1,218
639
509
3,503
3,393
3,250
3,480
3,514
3,348
3,182
2,979
2,9793,1823,3483,5143,4803,2503,3933,5035096391,2181,2831,3501,4721,3471,4501,5831,5831,7671,8741,970560546500493498506511126138141160165106130121136162176168141470330000000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
0
7
14
14
133
141
128
101
86
95
106
116
110
91
89
76
70
66
57
52
59
105
119
1,529
1,433
1,326
1,142
1,142
1,009
906
1,031
908
841
776
639
509
3,204
3,093
2,948
3,176
3,207
3,038
2,869
2,663
2,6632,8693,0383,2073,1762,9483,0933,2045096397768419081,0319061,0091,1421,1421,3261,4331,52911910559525766707689911101161069586101128141133141470330000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000505000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35
34
34
35
34
35
0
49
50
50
50
50
441
441
441
441
441
441
441
441
441
441
441
441
441
1,260
1,160
442
442
442
0
0
299
300
302
304
307
0
0
0
000307304302300299004424424421,1601,260441441441441441441441441441441441441441505050504903534353434350000000000000000000000000000000
> Total Liabilities 
0
19
19
23
35
40
56
65
69
76
81
85
89
98
106
111
86
95
99
78
82
84
84
100
104
4,643
2,806
3,820
3,446
7,325
20,028
11,117
10,226
9,492
3,611
3,051
2,155
4,614
3,286
2,488
3,028
4,521
5,370
4,106
3,529
4,666
6,393
5,266
4,122
6,077
6,892
6,118
6,382
6,026
6,026
5,184
5,100
5,078
4,361
3,955
4,194
6,843
5,725
43,619
45,561
47,711
44,818
45,974
45,361
45,066
44,495
44,49545,06645,36145,97444,81847,71145,56143,6195,7256,8434,1943,9554,3615,0785,1005,1846,0266,0266,3826,1186,8926,0774,1225,2666,3934,6663,5294,1065,3704,5213,0282,4883,2864,6142,1553,0513,6119,49210,22611,11720,0287,3253,4463,8202,8064,64310410084848278999586111106988985817669655640352319190
   > Total Current Liabilities 
0
4
4
2
4
4
17
23
22
26
21
25
24
30
33
36
33
36
36
25
28
26
26
29
31
4,643
2,806
3,820
3,446
7,325
20,028
11,117
10,226
9,492
3,611
3,051
2,155
4,614
3,286
2,488
3,028
4,521
5,370
4,106
3,529
4,666
6,393
5,266
4,122
6,063
5,855
5,178
5,541
5,344
5,344
4,656
4,680
4,767
4,164
3,873
4,190
6,840
5,723
6,282
8,350
10,628
7,864
9,151
8,672
8,494
8,064
8,0648,4948,6729,1517,86410,6288,3506,2825,7236,8404,1903,8734,1644,7674,6804,6565,3445,3445,5415,1785,8556,0634,1225,2666,3934,6663,5294,1065,3704,5213,0282,4883,2864,6142,1553,0513,6119,49210,22611,11720,0287,3253,4463,8202,8064,64331292626282536363336333024252126222317442440
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
140
75
37
0
158
94
55
8,217
284
190
92
1,228
266
178
90
432
301
576
426
54
16
7
0
0
249
537
477
410
381
746
564
457
427
437
447
417
307
195
311
390
498
506
514
522
541
551
5515415225145064983903111953074174474374274575647463814104775372490071654426576301432901782661,228921902848,2175594158037751400000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
284
0
0
0
266
0
0
0
301
576
426
54
16
7
0
0
0
175
101
25
381
268
154
38
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000381542683812510117500071654426576301000266000284000000000000000000000000000000000
       Accounts payable 
0
4
4
-4
0
0
9
10
10
12
10
12
10
14
12
11
12
14
11
25
2
0
0
0
0
897
460
794
312
379
615
1,045
1,731
2,284
1,248
1,011
888
1,474
1,853
1,379
2,571
4,195
4,769
3,605
3,450
4,625
6,386
5,266
4,122
5,814
5,318
4,701
5,131
4,598
4,041
4,092
4,223
4,340
3,727
3,426
3,773
5,535
5,261
5,767
7,869
10,130
7,358
8,637
8,150
7,953
7,513
7,5137,9538,1508,6377,35810,1307,8695,7675,2615,5353,7733,4263,7274,3404,2234,0924,0414,5985,1314,7015,3185,8144,1225,2666,3864,6253,4503,6054,7694,1952,5711,3791,8531,4748881,0111,2482,2841,7311,0456153793127944608970000225111412111214101210121010900-4440
       Other Current Liabilities 
0
1
1
5
4
4
8
14
12
14
11
13
14
16
21
25
20
22
24
25
27
26
26
29
31
3,575
2,240
2,958
3,134
6,707
19,129
9,827
8,495
6,710
1,865
1,923
1,267
2,849
1,230
935
457
326
601
501
79
41
7
0
0
6,063
5,318
4,701
5,131
365
4,598
4,092
4,261
4,340
3,727
3,426
3,773
6,533
5,528
5,767
7,869
-35,000
-35,000
-35,000
-35,000
541
-35,000
-35,000541-35,000-35,000-35,000-35,0007,8695,7675,5286,5333,7733,4263,7274,3404,2614,0924,5983655,1314,7015,3186,06300741795016013264579351,2302,8491,2671,9231,8656,7108,4959,82719,1296,7073,1342,9582,2403,5753129262627252422202521161413111412148445110
   > Long-term Liabilities 
0
15
15
21
31
36
39
42
47
50
60
60
65
69
73
75
54
59
63
54
54
58
58
71
73
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
1,037
940
841
682
682
528
420
311
197
82
4
3
2
37,337
37,211
37,083
36,954
36,823
36,689
36,572
36,431
36,43136,57236,68936,82336,95437,08337,21137,337234821973114205286826828419401,037130000000000000000000000007371585854546359547573696560605047423936312115150
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
211
191
171
151
130
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000130151171191211130000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,000
35,000
35,000
35,000
35,000
0
0
0
00035,00035,00035,00035,00035,000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,000
35,000
0
35,000
35,000
0
0
0
00035,00035,000035,00035,000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
-18
-18
-22
-29
-33
-54
-63
-66
-74
-79
-83
-87
-96
-105
-76
-86
-95
-99
-78
-82
-84
-84
-100
-104
1,146
551
1,915
604
-1,560
-13,468
4,330
2,372
-1,923
16,444
23,280
22,894
21,974
20,058
19,084
14,234
18,008
12,875
8,871
18,192
13,671
21,748
17,318
11,580
8,813
5,343
15,700
9,936
5,644
5,644
50,774
45,427
61,319
70,736
80,499
80,285
73,545
68,837
78,181
71,255
66,481
57,208
53,077
43,583
36,379
43,857
43,85736,37943,58353,07757,20866,48171,25578,18168,83773,54580,28580,49970,73661,31945,42750,7745,6445,6449,93615,7005,3438,81311,58017,31821,74813,67118,1928,87112,87518,00814,23419,08420,05821,97422,89423,28016,444-1,9232,3724,330-13,468-1,5606041,9155511,146-104-100-84-84-82-78-99-95-86-76-105-96-87-83-79-74-66-63-54-33-29-22-18-180
   Common Stock
0
23
0
23
23
23
23
23
23
23
23
23
23
112
112
112
112
112
112
112
112
112
112
112
112
214
214
236
237
25
26
28
30
30
36
40
42
44
45
47
48
56
57
59
80
80
110
110
110
116
119
162
165
165
165
13
14
18
19
21
22
22
22
25
25
26
26
27
27
28
29
292827272626252522222221191814131651651651621191161101101108080595756484745444240363030282625237236214214112112112112112112112112112112112112232323232323232323230230
   Retained Earnings Total Equity000-314,983-299,8020-278,118-268,644-260,877-255,748-247,738-241,315-236,294-230,974-224,594-219,054-214,428-208,758-204,155-197,556-192,528-186,857-180,537-174,389-169,467-163,153-157,990-151,667-144,613-136,552-129,856-123,257-116,633-112,230-105,690-101,743-94,280-91,205-85,779-797,017-83,217-66,51700000000-257-2540000000000000000000
   Accumulated Other Comprehensive Income 00000000000-339-3140-272-260-237-237-225-211-198-266-254-240-228-216-217-206-191-170-151-131-111-93-83-66-50-39-25-11-3-2-154-154-154-55,7430000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
64
64
0
0
0
0
0
0
0
0
64,933
69,723
84,004
88,121
89,252
110,688
124,982
128,542
134,160
136,647
142,294
144,042
154,504
157,431
160,479
176,102
176,744
191,104
191,597
192,007
195,554
197,751
213,094
213,926
214,237
217,273
269,815
270,007
292,275
307,011
321,793
328,001
329,271
329,692
346,800
349,348
0
356,984
368,033
0
0
0
000368,033356,9840349,348346,800329,692329,271328,001321,793307,011292,275270,007269,815217,273214,237213,926213,094197,751195,554192,007191,597191,104176,744176,102160,479157,431154,504144,042142,294136,647134,160128,542124,982110,68889,25288,12184,00469,72364,9330000000064640000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
152
175
152
152
152
152
152
152
152
152
152
152
64
64
64
64
64
64
64
64
64
64
64
64
112,419
56,924
61,050
61,160
64,935
69,726
84,015
88,146
89,292
110,738
125,048
128,625
134,253
136,758
142,425
144,193
154,675
157,623
160,685
176,319
176,960
191,332
191,838
192,261
195,821
197,949
213,306
214,151
0
214,475
270,075
270,279
292,275
307,325
322,132
328,001
329,271
329,692
346,800
349,348
355,220
356,984
368,033
371,815
373,934
390,081
390,081373,934371,815368,033356,984355,220349,348346,800329,692329,271328,001322,132307,325292,275270,279270,075214,4750214,151213,306197,949195,821192,261191,838191,332176,960176,319160,685157,623154,675144,193142,425136,758134,253128,625125,048110,73889,29288,14684,01569,72664,93561,16061,05056,924112,4196464646464646464646464641521521521521521521521521521521751520



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue81
Cost of Revenue-790
Gross Profit-709-709
 
Operating Income (+$)
Gross Profit-709
Operating Expense-51,211
Operating Income-51,920-51,920
 
Operating Expense (+$)
Research Development37,880
Selling General Administrative13,331
Selling And Marketing Expenses0
Operating Expense51,21151,211
 
Net Interest Income (+$)
Interest Income2,727
Interest Expense-0
Other Finance Cost-0
Net Interest Income2,727
 
Pretax Income (+$)
Operating Income-51,920
Net Interest Income2,727
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-48,818-55,022
EBIT - interestExpense = -51,920
-48,818
-48,818
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-51,920-48,818
Earnings Before Interest and Taxes (EBITDA)-51,130
 
After tax Income (+$)
Income Before Tax-48,818
Tax Provision-0
Net Income From Continuing Ops-50,141-48,818
Net Income-48,818
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses52,001
Total Other Income/Expenses Net3,102-2,727
 

Technical Analysis of Actinium Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Actinium Pharmaceuticals Inc. The general trend of Actinium Pharmaceuticals Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Actinium Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Actinium Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 8.58 < 10.24 < 10.46.

The bearish price targets are: 6.75 > 6.47 > 6.26.

Tweet this
Actinium Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Actinium Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Actinium Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartActinium Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Actinium Pharmaceuticals Inc. The current adx is .

Actinium Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartActinium Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Stochastic Oscillator ChartActinium Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartActinium Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartActinium Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Williams %R ChartActinium Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Average True Range (ATR) ChartActinium Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartActinium Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartActinium Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Actinium Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-17MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-06-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-06-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Actinium Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Actinium Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose7.240
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Actinium Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Actinium Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Actinium Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Actinium Pharmaceuticals Inc

I send you an email if I find something interesting about Actinium Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Actinium Pharmaceuticals Inc.

Receive notifications about Actinium Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.